| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
36,160,000 |
| Market
Cap: |
48.27(M) |
| Last
Volume: |
961,734 |
Avg
Vol: |
521,326 |
| 52
Week Range: |
$0.49 - $1.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Imunon is a clinical stage biotechnology company. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for the treatment of ovarian cancer. ThermoDox®, Co.'s proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications, which is being managed though Co.'s wholly owned subsidiary, Celsion GmbH. Additionally, Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Borys Nicholas |
VP & Chief Medical Officer |
• – – |
2008-11-19 |
4 |
B |
$2.50 |
$1,010 |
D/D |
404 |
8,404 |
2.66 |
- |
|
| Link Max |
Director |
– • – |
2008-11-17 |
4 |
B |
$2.60 |
$19,599 |
D/D |
7,100 |
120,462 |
2.39 |
- |
|
| Tardugno Michael H |
President & CEO |
• • – |
2008-11-14 |
4 |
B |
$2.83 |
$8,501 |
D/D |
3,000 |
32,167 |
2.81 |
- |
|
| Borys Nicholas |
VP & Chief Medical Officer |
• – – |
2008-06-18 |
4 |
B |
$4.10 |
$12,300 |
D/D |
3,000 |
8,000 |
2.74 |
- |
|
| Tardugno Michael H |
President & CEO |
• • – |
2008-06-16 |
4/A |
B |
$4.38 |
$10,989 |
D/D |
2,500 |
29,167 |
2.81 |
- |
|
| Tardugno Michael H |
President & CEO |
• • – |
2008-06-16 |
4 |
A |
$4.38 |
$10,989 |
D/D |
2,500 |
29,167 |
|
- |
|
| Borys Nicholas |
VP & Chief Medical OfficerOffi |
• – – |
2008-05-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
| Pace Gary W |
Director |
– • – |
2008-02-26 |
4 |
B |
$6.27 |
$25,076 |
D/D |
4,000 |
24,349 |
2.39 |
- |
|
| Pace Gary W |
Director |
– • – |
2008-02-25 |
4 |
B |
$6.17 |
$12,340 |
D/D |
2,000 |
20,349 |
2.39 |
- |
|
| Tardugno Michael H |
Chief Executive Officer |
• – – |
2008-01-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,333 |
122,662 |
|
- |
|
| Link Max |
Director |
– • – |
2007-05-18 |
4 |
B |
$4.84 |
$48,400 |
D/D |
10,000 |
113,362 |
2.39 |
- |
|
| Tardugno Michael H |
President, CEO |
• – – |
2007-05-17 |
4 |
B |
$4.81 |
$11,473 |
D/D |
2,384 |
10,000 |
2.74 |
- |
|
| Link Max |
Director |
– • – |
2007-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,896 |
103,362 |
|
- |
|
| Link Max |
Director |
– • – |
2007-02-27 |
4 |
B |
$3.49 |
$34,937 |
D/D |
10,000 |
97,466 |
2.39 |
- |
|
| Link Max |
Director |
– • – |
2007-02-26 |
4 |
B |
$3.50 |
$35,027 |
D/D |
10,000 |
87,466 |
2.39 |
- |
|
| Weaver Gregory L |
Director |
– • – |
2007-02-23 |
4 |
B |
$3.50 |
$35,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Tardugno Michael H |
President, CEO |
• – – |
2007-02-23 |
4 |
B |
$3.46 |
$26,351 |
D/D |
7,616 |
7,616 |
2.74 |
- |
|
| Hahne William |
VP of Research & Development |
• – – |
2007-02-23 |
4 |
B |
$3.55 |
$21,300 |
D/D |
6,000 |
15,100 |
2.74 |
- |
|
| Hahne William |
VP of Research & Development |
• – – |
2006-10-03 |
4 |
A |
$2.44 |
$12,444 |
D/D |
5,100 |
9,100 |
|
- |
|
| Hahne William |
VP - Clin. Dev. & Med. Affairs |
• – – |
2006-05-12 |
4 |
B |
$3.75 |
$7,500 |
D/D |
2,000 |
4,000 |
2.74 |
- |
|
| Hahne William |
VP - Clin. Dev. & Med. Affairs |
• – – |
2006-03-20 |
4 |
B |
$4.19 |
$4,198 |
D/D |
1,000 |
2,000 |
2.66 |
- |
|
| Link Max |
Director |
– • – |
2006-03-17 |
4 |
B |
$4.03 |
$40,300 |
D/D |
10,000 |
70,800 |
2.39 |
- |
|
| Oleck Michael |
VP - Operations |
• – – |
2006-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
8,534 |
|
- |
|
| Olanoff Lawrence S |
President & CEO |
• – – |
2006-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,510 |
33,786 |
|
- |
|
| Finkle Carolyn |
VP - Regulatory Affairs |
• – – |
2006-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,369 |
2,369 |
|
- |
|
228 Records found
|
|
Page 8 of 10 |
|
|
